

# Saskatchewan Cancer Agency Integration with PIP

Alex Martinson, BSP, ACPR  
Provincial Manager Oncology Drug Programs, Access and Analytics  
Saskatchewan Cancer Agency



1

## Learning objectives

- Describe Saskatchewan Cancer Agency pharmacy professional roles when a patient is prescribed a cancer treatment medication.
- Explain the “5 Ws” (why, who, where, when and what) of SCA medications that will be captured on PIP/ eHealth Viewer.
- Outline the specific information regarding cancer treatment medications that will be available on PIP/eHealth Viewer.
- Summarize how to incorporate cancer treatment medications now viewed on PIP/eHealth Viewer into practice and how to support patients undergoing cancer treatment.
- Identify quality oncology resources and how to access them.


2

## Saskatchewan Cancer Agency (SCA) Pharmacy Services

3

### Our Service

- Most comprehensive pharmacy service and drug funding of any dedicated cancer program in Canada



4

4

## SCA Pharmacy Services

- Allan Blair Cancer Centre (ABCC) Regina
  - 306-766-2816
- Saskatoon Cancer Centre (SCC)
  - 306-655-2680
- Hours of Operation
  - 0800-1630 Monday to Friday

5

## Community Oncology Program of Saskatchewan (COPS)

16 locations in the Saskatchewan Health Authority accommodate treatment closer to home

### Northern COPS Centres

- Humboldt
- Kindersley
- Lloydminster
- Meadow Lake
- Melfort
- Nipawin
- North Battleford
- Prince Albert
- Tisdale
- Flin Flon \*\*

### Southern COPS Centres

- Estevan
- Melville
- Moose Jaw
- Moosomin
- Swift Current
- Weyburn
- Yorkton

6

## Specialized Pharmacist Role

- Provide expertise on pharmacokinetics, pharmacodynamics, pharmacogenomics of drugs
- Assist with drug treatment selection – evidence-based
- Ensure policies and procedures exist to deliver treatments in a safe and effective manner
- Navigate reimbursement
- Patient education
- Manage toxicities and drug interactions

7

## Regulated Pharmacy Technicians

- Interview patients and record BPMH on electronic chart
- Inventory management, shipping and provincial distribution
- Medication order entry
- Oral dispensary and triage desk
- Final product check for take home medications
- Preparation of hazardous medications
- Final product check for IV preparations
- Coordinating external injection programs

8

# SCA Drug Formulary

- Distinct from Sask. Prescription Drug Plan and Hospital Benefit Drug List
- Outlines authorized prescribers, funded drugs with eligibility criteria
- Administered and updated by SCA Pharmacy & Therapeutics Committee monthly
- Published on our website: [www.saskcancer.ca](http://www.saskcancer.ca)

8/19/2022

9

9

Sask cancer AGENCY

Home Search ...

PATIENTS & FAMILIES SCREENING PREVENTION HEALTH PROFESSIONALS RESEARCH ABOUT DONATE

Home / Health Professionals

## Health Professionals

Information for healthcare professionals about cancer care.

**CLINICAL RESOURCES**

- > Immunization Guideline 2021
- > Clinical Practice Guidelines
- > Follow Up Guidelines
- > SHA/SCA Provincial Requisitions

**CANCER SCREENING RESOURCES**

- > Breast Cancer Screening
- > Cervical Cancer Screening
- > Colorectal Cancer Screening

**DRUG FUNDING**

- > Drug Formulary
- > Frequently Asked Questions
- > Request for Extended Cancer Drug Supplies Policy
- > pan-Canadian Oncology Drug Review

**WAIT TIMES INFORMATION**

- > Charts and Definitions
- > Cancer Surgery

10

www.saskcancer.ca



SASKATCHEWAN CANCER AGENCY DRUG FORMULARY

Updated as of June 1, 2022

Disclaimer: The Saskatchewan Cancer Agency Drug Formulary is an information-only resource that identifies the funding status and eligibility requirements of cancer treatment drugs and some supportive drugs used to care for cancer patients in Saskatchewan. It is current only as of the date listed on the Drug Formulary, and is not intended to constitute medical advice.

DRUG	DOSAGE FORM	STRENGTH	SPECIAL STATUS	DISEASE SITE GROUP	CANCER SITE	FUNDED INDICATIONS and ELIGIBILITY REQUIREMENTS	FUNDING NOTES
abiraterone	tablet	250 mg 500 mg		Genitourinary	Prostate (mCRPC)	Metastatic* castration-sensitive prostate cancer (mCRPC) in combination with prednisone and androgen deprivation therapy (ADT) in patients who have had no prior ADT in the metastatic setting, or initiated ADT within 6 months in the metastatic setting with no disease progression  Abiraterone may continue until disease progression or unacceptable toxicity	*Metastatic prostate cancer is interpreted as distant metastatic disease (i.e., positive bone scan or metastatic lesions on radiologic imaging for soft tissue, patients with disease limited to regional pelvic lymph nodes only are not eligible)  Patients who previously received adjuvant androgen deprivation therapy (ADT) in the non-metastatic setting are eligible as long as ADT was completed ≥1 year prior to initiation of abiraterone  Patients who received recent docetaxel chemotherapy for the treatment of metastatic castration-sensitive prostate cancer (mCRPC) within the past 3 months are eligible if they have not experienced disease progression  Patients unable to tolerate abiraterone plus prednisone may be switched to either apalutamide or enzalutamide for treatment of mCRPC if there is no disease progression  Patients who experience disease progression on abiraterone plus prednisone for treatment of mCRPC are eligible for enzalutamide for treatment of metastatic castration-resistant prostate cancer (mCRPC) if they are unable to tolerate or are not candidates for other therapeutic choices (i.e., chemotherapy) provided they have previously not experienced disease progression after prior treatment with other androgen receptor axis therapies (ARATs) (e.g., apalutamide, darolutamide) in any setting
				Genitourinary	Prostate (mCRPC)	Metastatic castration resistant prostate cancer* (mCRPC) in combination with prednisone	*Castration resistant prostate cancer is defined as 3 consecutive rises in prostate-specific antigen (PSA) at least 1 week apart with the last PSA >2 mg/L, __ progression or appearance of ≥2 lesions on bone scan or in soft tissue, during continuous androgen deprivation therapy (ADT) with castrate testosterone levels (<1.7 nmol/L)  Abiraterone is funded in patients who have experienced disease progression after prior treatment with other androgen receptor axis therapies (ARATs) (e.g., enzalutamide) in patients who are unable to tolerate or are not candidates for other therapeutic choices (i.e., chemotherapy)
Abraxane (paclitaxel-nanoparticle albumin bound [ nab ])	vial	100 mg		Breast	Breast, Advanced	locally advanced unresectable or metastatic breast cancer in patients who have experienced previous anaphylaxis or anaphylactoid reactions with conventional paclitaxel or docetaxel infusions or who have significant contraindications to use of taxane pre-medication and in whom further use of a taxane is appropriate	An example of a significant contraindication to taxane pre-medication would be in patients with uncontrolled diabetes
				Gastrointestinal	Pancreas	locally advanced unresectable or metastatic adenocarcinoma of the pancreas in combination with gemcitabine as first or second-line (after FOLFIRINOX) treatment	
				Gynecology	Multiple	locally advanced unresectable or metastatic ovarian, fallopian tube, primary peritoneal, endometrial or cervical cancer in combination with platinum-based therapy in patients who have experienced previous anaphylaxis or anaphylactoid reactions with conventional paclitaxel infusions or who have significant contraindications to use of taxane pre-medication and in whom further use of a taxane is appropriate	

8/19/2022

11

11

PIP Integration

12

## Project Objective

- To capture medications dispensed from the Saskatchewan Cancer Agency into PIP to ensure patient safety and reduce risk by having a more complete patient profile on PIP for Saskatchewan residents

13

## Why are we doing this

- Provide ability for health care teams outside of SCA to know when a patient is on a cancer medication
- Ensure informed health care decisions are made with all the available medication information
- Increase safety and accuracy of medication histories and profiles
- Allow access to information from a physician or nurse practitioner's clinic, emergency department or community pharmacy

14

## Who is involved/affected

- College of Physicians and Surgeons of Saskatchewan
- College of Registered Nurses of Saskatchewan
- Saskatchewan College of Pharmacy Professionals
- Other users of PIP – dentists, midwives, podiatrists
- eHealth Saskatchewan
- medSask
- Ministry of Health (DPEBB)
- Saskatchewan Health Authority
- Saskatchewan Cancer Agency (SCA)



15

## Where will the info display

- PIP
- eHR Viewer
- Preadmission Medication List
- My Sask Health Record

16

**PPFTEST\_AA**  
 111425 47th AVE NW  
 MOOSE JAW, Saskatchewan  
 S0G 0V0  
 HSN: 210 123 001

\_\_\_\_\_ HEALTH REGION

**CONFIDENTIALITY NOTICE:** The content of this communication is confidential and contains personal health information. It is intended solely for the use of the patient's health care provider. If you have received this communication in error, please notify the sender immediately and destroy all original and copies of the misdirected communication.

**PREADMISSION MEDICATION LIST / PRESCRIBER ORDER FORM**  
 Keep this form with the Prescriber Orders - Must not be thrown from patient chart.

Medication Name	Dose	Route	Interval	Time / Day of Week / Last Dose	Prescriber Orders		Comments / Rationale
					Continue	Change / STOP	
DOXORUBICIN 2 MG/ML VIAL (Doxorubicin HCL)		Intravenous					
2022-Apr-13 SALIM, MUHAMMAD (MD)							
ONDANSETRON 8MG/8 MG TABLET (Ondansetron)		Oral					
2022-Apr-13 SALIM, MUHAMMAD (MD)							
PMS-DEXAMETHASONE 4 MG TAB (Dexamethasone)		Oral					
2022-Apr-13 SALIM, MUHAMMAD (MD)							
etoposide 10 20 mg/1 mL - Oral use-00000000		Undertified					
2022-Apr-13 SALIM, MUHAMMAD (MD)							
ibuprofen tab 200 mg (NasalEE Triaj)-00000000		Undertified					
2022-Apr-13 SALIM, MUHAMMAD (MD)							

Medication list continues on next page.

Comments / Concerns / Follow-up: \_\_\_\_\_  
 Prescriber: \_\_\_\_\_ (print)  
 \_\_\_\_\_ (sign)  
 Date: \_\_\_\_\_ Time: \_\_\_\_\_

Completed by: \_\_\_\_\_ Title: \_\_\_\_\_ Date: \_\_\_\_\_ Time: \_\_\_\_\_  
 Reviewed by: \_\_\_\_\_ Title: \_\_\_\_\_ Date: \_\_\_\_\_ Time: \_\_\_\_\_

Form Communication: Initial baseline action(s) completed.  
 Processed \_\_\_\_\_ Faxed \_\_\_\_\_ MAR \_\_\_\_\_

Generated from the Pharmaceutical Information Program (PIP), Saskatchewan Ministry of Health on 2022-Jun-14.  
 Page 2 of 3

17

<https://skphr.stg.telushealthspace.com/ng/#/pages/Medicalrecord-medication>

CA Service Desk Ma... Gateway On-line HP Application Life... Health Canada Dru... Pharmaceutical Info... Pharmacy Associat... Root Cause Analys... Other favorites

**MySaskHealthRecord Saskatchewan** Prescription History

Need Help? FRED MLAB FM

Sort by Medication Name Date Prescribed Instructions Prescribed By

- VEPESID 50 MG CAPSULE**  
 Prescribed By SALIM, MUHAMMAD  
 Date Prescribed Jul 4, 2022  
 Instructions The "instructions" are not known for this prescription.  
[View Refills](#) [Add/View Comments](#)
- APO-PREDNISONE 5 MG TABLET**  
 Prescribed By SALIM, MUHAMMAD  
 Date Prescribed Jul 4, 2022  
 Instructions The "instructions" are not known for this prescription.  
[View Refills](#) [Add/View Comments](#)
- APO-PREDNISONE 50 MG TABLET**  
 Prescribed By SALIM, MUHAMMAD  
 Date Prescribed Jun 23, 2022  
 Instructions The "instructions" are not known for this prescription.  
[View Refills](#) [Add/View Comments](#)
- ETOPOSID 20 MG/ML VIAL**  
 Prescribed By SALIM, MUHAMMAD  
 Date Prescribed Jun 23, 2022  
 Instructions The "instructions" are not known for this prescription.  
[View Refills](#) [Add/View Comments](#)
- APO-DEXAMETHASONE 0.5 MG TAB**  
 Prescribed By Prescriber, Alberta  
 Date Prescribed Jun 23, 2022
- GRASTOFIL 300MCG/0.5ML SYRINGE**  
 Prescribed By SALIM, MUHAMMAD  
 Date Prescribed Jun 23, 2022

**Report an Error**  
 If provincial data appears to be incorrect, report the error by clicking [here](#)

+

18

## When - Go live date **August 29**

- Medications dispensed on and after this date will appear in PIP
- Historical medications WILL NOT appear in PIP
- Data will transmit to PIP 3 times a day

19

## What will display

- Medications dispensed by the SCA pharmacies
- Including
  - Special Access Program (SAP) medications accessed thru Health Canada
  - Patient Access Program (PAP) medications provided compassionately by manufacturers
  - Clinical Trials

20

## Including cancer treatments administered at:

- ABCC and SCC
- SCA affiliated COPS centres
- Outpatient Treatment Centre (Regina)
- Outpatient Day Centre (Saskatoon)
- Home Injection Programs
- SHA hospitals for inpatients
- Jim Pattison Children's Hospital

21

## Out of Province

- Patients with Sask Health coverage may have prescriptions filled out of province
  - Receiving treatment at another cancer centre
  - Specialty pharmacy dispensing required
- Patients with health coverage from other provinces may be treated in Sask
  - However without a valid sask health card number these patients will not appear in PIP

22

## Types of Medications

- Injectable Cancer Therapy
  - Includes IV, IM and Subcutaneous
- Oral Cancer Therapy
- Supportive Care Medications
  - Bisphosphonates
- Post Chemotherapy Medications
  - Dexamethasone and ondansetron
  - granulocyte colony stimulating factors (Grastofil®)

23

## Pre-Medications

- A **single dose** of medication given prior to treatment to minimize side effects like nausea and vomiting and treatment related reactions
  - **WILL NOT APPEAR IN PIP**
- Examples include dexamethasone, ondansetron, metoclopramide, diphenhydramine, famotidine, lorazepam
- **EXCEPTIONS** – Emend®, Akynzeo®

24

## What Information is being sent from SCA to PIP

- HSN of patient
- Date of dispense
- Prescription number
- DIN of the drug product
- Fill quantity
- Days supply
- Provider identification for dispense (physician)
- Pharmacy site ID number – ABCC or SCC

25

The screenshot displays a patient profile for PIPTTEST, AA (HSN: 210 123 001). Patient details include Gender: Male, Age: 58 Years, Home: 1964-Jan-28, and Work: (blank). A 'NEW Rx' button is visible. The interface is divided into several sections:

- Active Prescriptions:** Includes tabs for ACTIVE RX, RX HISTORY, and ALLERGIES. It lists various prescriptions with columns for DRUG, DOSE, FREQ, DAYS, and STATUS.
 

DRUG	DOSE	FREQ	DAYS	STATUS
Continuous				
Short-Term				
External Rx Information				
etoposide inl 20...		20		Filled
ONDANSETRON ODT 8...		29		Filled
PMS-DEXAMETHASONE...		24		Filled
ribociclib Tab 20...		20		Filled
- Recently Active Prescriptions:** Lists DOXORUBICIN 2 MG/L... with a status of Filled.
- History of Dispensed Drugs (4 Months):** A table showing dispensed drugs with columns for FILL DATE, DRUG NAME (DIN/NPN), QTY, FREQUENCY, DAYS, and PRESCRIBER PHARMACY.
 

FILL DATE	DRUG NAME DIN/NPN	QTY	FREQUENCY	DAYS	PRESCRIBER PHARMACY
2022-Jun-13	DOXORUBICIN 2 MG/L... 02381982	1	VIAL	1	Salm, Muhammad Saskatoon Cancer Centre
2022-Jun-13	ONDANSETRON ODT 8... 02481731	30	TAB	30	Salm, Muhammad Saskatoon Cancer Centre
2022-Jun-13	PMS-DEXAMETHASONE... 01964070	30	TAB	25	Salm, Muhammad Saskatoon Cancer Centre
2022-Jun-13	etoposide inl 20...	2	EA	21	Salm, Muhammad Saskatoon Cancer Centre
2022-Jun-13	ribociclib tab 20...	21	EA	21	Salm, Muhammad Saskatoon Cancer Centre

26

## How to identify the prescription was filled by SCA

History of Dispensed Drugs (4 Months)				
FILL DATE	DRUG NAME DIN/NPN	QTY FREQUENCY	DAYS	PRESCRIBER PHARMACY
2022-Jun-09	ADCETRIS 50 MG VI... 02401347	1 VIAL	1	Salim, Muhammad Allan Blair Cancer Centre
2022-Jun-09	Fosaprepitant 150...	1 EA	0	Salim, Muhammad Allan Blair Cancer Centre
2022-Jun-09	GRASTOFIL 300MCG/... 02441489	1 VIAL	0	Salim, Muhammad Allan Blair Cancer Centre
2022-Jun-09	NAT-ONDANSETRON 8... 02417847	30 TAB	14	Salim, Muhammad Allan Blair Cancer Centre
2022-Jun-09	PMS-DEXAMETHASONE... 01964070	20 TAB	0	Salim, Muhammad Allan Blair Cancer Centre
2022-Jun-09	TEVA-DIMENATE 50... 00021423	30 TAB	5	Prescriber, Unknown Allan Blair Cancer Centre
2022-Jun-09	selinexor SAP tab...	20 EA	21	Prescriber, Alberta Allan Blair Cancer Centre

Dispensing pharmacy will appear as

- Allan Blair Cancer Centre
- Saskatoon Cancer Centre

27

## Drug name

- Based on DIN
- Specific brand name
  - Tamoxifen
    - APO-Tamoxifen
    - Nolvadex-D
  - Ifosfamide
    - Ifex

[https://efq-pip.ehealthsask.ca/PIN\\_GUI/](https://efq-pip.ehealthsask.ca/PIN_GUI/)

<https://efq-pip.ehealthsask.ca/>

### DRUG SEARCH RESULTS

02241356

● IFEX 3 GRAM VIAL

28

History of Dispensed Drugs (4 Months)				
FILL DATE	DRUG NAME DIN/NPN	QTY FREQUENCY	DAYS	PRESCRIBER PHARMACY
2022-Jun-13	<u>DOXORUBICIN 2 MG/...</u> 02381982	1 VIAL	1	Salim, Muhammad Saskatoon Cancer Centre
2022-Jun-13	<u>ONDANSETRON ODT 8...</u> 02481731	30 TAB	30	Salim, Muhammad Saskatoon Cancer Centre
2022-Jun-13	<u>PMS-DEXAMETHASONE...</u> 01964070	30 TAB	25	Salim, Muhammad Saskatoon Cancer Centre
2022-Jun-13	<u>etoposide inj 20 ...</u>	2 EA	21	Salim, Muhammad Saskatoon Cancer Centre
2022-Jun-13	<u>ribociclib tab 20...</u>	21 EA	21	Salim, Muhammad Saskatoon Cancer Centre

29

Fill Date
<ul style="list-style-type: none"> <li>• <b>Fill Date is based on the date of prescription entry</b></li> <li>• Prescriptions are generally entered ahead of time</li> <li>• Fill Date may not equal start date of chemo cycle or date of administration</li> </ul>

30

## What does not appear in PIP

- **SIG/Instructions do not transmit from SCA to PIP**
- Patients should refer to the label on their prescriptions for instructions

31

The screenshot displays a prescription management interface with the following details:

Rx DETAILS   DISPENSING HISTORY   STATUS HISTORY   NOTES			
RENEW Rx   DISCONTINUE Rx   HOLD Rx   CANCEL REFILLS			
DRUG ⓘ			MONOGRAPH
<b>PMS-DEXAMETHASONE 4 MG TAB</b>			
DIN/NPN	01964070		
GENERIC FORM	Dexamethasone 4 mg Oral Tablet		
INDICATION	Not available		
SIG INSTRUCTIONS	<u>Dosage specification is not known.</u> The source of this information is ADAPT. The information received may not be complete. See the dispense details for more information.		
QTY LAST DISPENSED	30 TAB	LAST DISPENSED	2022-Jun-13
RENEW DATE	Not available	AMT DISPENSED	100 %
ROUTE	Oral	BASE COST / DAY	\$0.00
DRUG USE	Short term	COMPLIANCE PKG	Not required
SUBSTITUTION	Allowed	DISP INTERVAL	Not available
		TOTAL DAYS SUPPLY	Not available
PRESCRIBER	Salim, Muhammad (MD)	PHONE	(306) 7662213
RX EFFECTIVE	2022-Jun-13	RX EXPIRY	2023-Jun-13
LAST FILLED AT	Saskatoon Cancer Centre	PHONE	(306) 655-2680
PIP RX NUMBER	0000-6FFW	STATUS	Filled

32

## C# compound attribute

DRUG	DOSE	FREQ	DAYS	STATUS
<b>External Rx Information</b>				
C# bexarotene SAP ca...	26			Filled
C# etoposide inj 20...	24			Filled
RAT-ONDANSETRON B...	26			Filled

Important Note:  
**will NOT** automatically  
 DI check in PIP

- clinical trial drugs
- compounds

33

## ePrescribers and DI Checking

Drug Product/DIN/NPN   Sounds Like

Drug Strength

Drug Route

Drug Form

NOTE: The result list may not contain all approved drugs

Drug interaction checks will be performed against all drugs on the Active Prescription profile. You may optionally include any of the drugs from the Recently Active list below.

**INCLUDE ALL**

ONDANSETRON ODT 4 MG TABLET

ACH-TEMOZOLOMIDE 100 MG CAP

PMS-DEXAMETHASONE 4 MG TAB

DOXORUBICIN 2 MG/ML VIAL

34

# Where can you find more information about your patient?

TEST, Dave X 1978-Mar-01 (44 years) M

Demographics

Gender	M	Address	10 Testing Lane Regina, SK, S4P4L4	Alternate Names		Identifiers	NA, SK MDN
Date of Birth	1978-Mar-01	Phone	tel:306555-5555				

TEST, Dave X 1978-Mar-01 (44 years) M

Clinical Documents

Showing 2021-07-04 to 2022-07-05

View By Category Sort By Date

- Demographics
- Consults/Referrals (6)
- Discharge & Transfer (9)
- Progress Notes (3)

TEST, Dave X 1978-Mar-01 (44 years) M

Clinical Documents

Showing 2021-07-04 to 2022-07-05

View By Category Sort By Date

- Demographics
- Consults/Referrals (6)
- Discharge & Transfer (9)
- Progress Notes (3)

- 2022-Jan-13 SCA Review/Follow-up FOSTER, BRENDA
- 2022-Jan-13 SCA Hospital Admission FOSTER, BRENDA
- 2022-Jan-13 SCA Review/Follow-up FOSTER, BRENDA

35

TEST, Dave X 1978-Mar-01 (44 years) M

Clinical Documents

Showing 2021-07-04 to 2022-07-05

View By Category Sort By Date

- Demographics
- Consults/Referrals (6)
- Discharge & Transfer (9)
- Progress Notes (3)

2022-Jan-13 SCA Review/Follow-up FOSTER, BRENDA

2022-Jan-13 SCA Hospital Admission FOSTER, BRENDA

2022-Jan-13 SCA Review/Follow-up FOSTER, BRENDA

SCA Review/Follow-up (5 months ago)

**Head & Neck - Review - On Treatment/Follow-Up**

**TESTING REVIEWPATIENT/FOLLOW-UP NOTE TYPE**

Date Seen: Jan 13, 2022

**Summary of Care**  
HPI is not available for this patient.

**Visit Reason**  
Chief Complaint is not available for this patient.

**Physical Exam**  
Physical Exam-Author is not available for this patient.

**Impression**  
Impression is not available for this patient.


**Plan**  
Plan is not available for this patient.

If the patient develops any new problems in the interim, the patient is encouraged to contact the clinic earlier.

36

How can you use this information in your practice?

37



38

## Managing Side Effects of Cancer Treatments

- Patients are provided with counselling on all cancer medications
- Written information is also provided
- Patients have contact information for their oncologist
- Refer back to SCA when needed

39

## Febrile Neutropenia

- Neutrophils -  $< 0.5$  or  $< 1.0$  with a predicted decline to  $< 0.5$  within 48 hours
- Fever - a single temperature of  $> 38.3^{\circ}\text{C}$  or a temperature of  $> 38^{\circ}\text{C}$  sustained for over one hour)
- Risk factors: cytotoxic agent, dose intensity of the regimen, concomitant chemoradiation therapy, severity and duration of neutropenia, patient factors

40

## Febrile Neutropenia is a medical emergency

- Seek medical attention **immediately**
- **DO NOT** take acetaminophen, ibuprofen or ASA until healthcare provider has been contacted
- **Treat empirically with broad spectrum antibiotics**

41

## Take Home Prescription

**Saskatchewan Cancer Agency**

Allan Blair Cancer Centre  
6125 Dowling Avenue, Regina SK  
Tel: (306) 766-2377

Saskatoon Cancer Centre  
28 Campus Drive, Saskatoon, SK  
Tel: (306) 653-6362

**Low Emetic Risk Take Home Prescriptions Post-Chemotherapy**  
Complete and sign each prescription required for at home treatment.

Date: \_\_\_\_\_ Printed Physician Name: \_\_\_\_\_

**FOR FAXED PRESCRIPTIONS, PLEASE CALL PATIENT WHEN MEDICATIONS ARE READY FOR PICK-UP AT COMMUNITY PHARMACY**

Choose one:

**Metoclopramide 10 mg**  
10 mg PO QID PRN to control nausea/vomiting  
Dispense: 60 x 10 mg  
Refill: x \_\_\_\_\_

OR

**Prochlorperazine 10 mg**  
10 mg PO QID PRN to control nausea/vomiting  
Dispense: 60 x 10 mg  
Refill: x \_\_\_\_\_

Physician Signature: \_\_\_\_\_

Other: \_\_\_\_\_  
Physician Signature: \_\_\_\_\_

Other: \_\_\_\_\_  
Physician Signature: \_\_\_\_\_

**Prescription reviewed by SCA pharmacist.  
Any drug interactions with current medications have been addressed.**

42

## Nausea and Vomiting

- Did the patient have dexamethasone and ondansetron filled by the SCA pharmacy?
- Did they take it according to the directions?
  
- Did the patient receive a take home prescription?
- Did they fill it?
  
- Nausea and Vomiting are assessed by the oncologist/pharmacist at each follow up visit
- Encourage the patient to keep a symptom diary

43

## Diarrhea

- Can be a symptom of mucosal damage secondary to **chemotherapy** or radiotherapy
  - Expected side effect of some chemotherapy
    - irinotecan, capecitabine, fluorouracil, methotrexate, cytarabine
  
- Can be result of immune related toxicity secondary to **immunotherapy**

44

## Diarrhea Management

- For chemotherapy induced
  - Loperamide
    - Intensive loperamide regimen - Irinotecan
  - Diphenoxylate
  - Octreotide
- For immunotherapy induced
  - Mild - supportive care
  - Moderate to severe - **Prednisone**

45

## Immunotherapy

- Ipilimumab (Yervoy®)
- Pembrolizumab (Keytruda®)
- Nivolumab (Opdivo®)
- Durvalumab (Imfinzi®)
- Atezolizumab (Tecentriq®)
- Avelumab (Bavencio®)

46

## Identifying Drug Interactions

- Medications patients were taking prior to initiation of cancer treatment have been reviewed by the SCA pharmacist for drug interactions
  - Please contact SCA pharmacy if a significant drug interaction is noted and it is unclear if it was addressed
- Prescriptions for new medications started after cancer treatment initiation will need to be reviewed for drug interactions by the community pharmacist

47

## How to manage drug interactions

- Was the patient on the interacting medication prior to starting cancer treatment?
- Is the interaction significant?
- Can an adjustment be made to the non-cancer medication?
  - Is there an alternate agent that does not have the same risk
- If the risk is significant and no alteration can be made to the non-cancer medication, contact the oncologist

48

## Important Notes

Prescription reviewed by SCA pharmacist.  
Any drug interactions with current  
medications have been addressed.

- Not all prescriptions written by an oncologist are reviewed by the SCA Pharmacists
  - Prescriptions for supportive care medications may be sent directly to the community pharmacy
- Not all prescriptions for 'cancer' drugs are written by an oncologist
  - Tamoxifen for breast cancer prevention written by a GP would not be reviewed by an SCA pharmacist

49

## Nausea and Vomiting – Anti-nauseants

- Dispensed by SCA
  - Dexamethasone
  - Ondansetron
- Dispensed by community pharmacy
  - Metoclopramide
  - Prochlorperazine
  - Dimenhydrinate
  - Olanzapine

50

## Tamoxifen and Antidepressants

- Inhibitors of CYP2D6, inhibit activation of tamoxifen (prodrug) to its major active metabolite
- Decrease clinical effectiveness  
= Decrease Disease Free Survival
- Strong inhibitors – paroxetine, fluoxetine, bupropion
- Weak inhibitors – citalopram, desvenlafaxine, escitalopram
- Fluvoxamine and venlafaxine do not significantly inhibit CYP2D6

51

## Acid Reducing Agents and TKI's

- Stomach pH is an important factor in the solubility and absorption of Tyrosine Kinase Inhibitors (TKI's)
  - End in 'tinib'
  - Afatinib, erlotinib, gefitinib, and osimertinib
- Avoid proton pump inhibitors if possible
- Separate from H2 receptor antagonists – 10 hours after last dose or 2 hours before next dose
- Separate from antacids by several hours

52

## Bisphosphonates

- Zoledronic acid and pamidronate are commonly prescribed for the prevention of skeletal related events in patients with bone metastases
- Patients may be prescribed a bisphosphonate for prevention of osteoporosis by their GP
- Increased risk of hypocalcemia, renal impairment, osteonecrosis of the jaw

53

## Steroids

- Dexamethasone is commonly prescribed
  - for management of chemotherapy induced nausea and vomiting,
  - as part of some treatment protocols
  - for management of side effects related to radiation therapy
- Prednisone is prescribed in combination with many prostate cancer treatments
- Patients may also be prescribed steroids by their GP for the management of various conditions or emergency room physicians for management of side effects related to immunotherapy

54

## Paxlovid and Cancer Treatment

- Numerous drug interactions with various cancer therapies
- Cancer patients receiving active treatment should be counselled to call the cancer centre for prescribing of Paxlovid


Immunocompromised with **complex disease state**:

- Active treatment for cancer
- Moderate to severe primary immunodeficiency
- Hematopoietic stem cell transplant
- Solid organ transplant
- Yes to any → Refer patient to the appropriate specialist only—SHA Early COVID Therapeutics Team, Cancer Specialist or Transplant Specialist (Note: Transplant and Cancer patients—if unable to reach the specialist, call 811)

55

## Influenza Immunization

- Recommended that patients on chemotherapy, targeted treatment and immunotherapy receive flu shot
- Exceptions
  - Stem cell transplant within previous 4 months (6 months for pediatrics)
  - CTLA-4 Inhibitors – Ipilimumab
  - Patients on clinical trials



56

## Drug Interaction Checking Software

- LexiComp
- Micromedex
- Drugs.com

57

## Oncology Resources

58

# Oncology Resources

- Sask Cancer Agency Website
- BC Cancer Agency Website
- Cancer Care Ontario Website

25

59

**Sask cancer**  
AGENCY

Home Search ...

PATIENTS & FAMILIES SCREENING PREVENTION HEALTH PROFESSIONALS RESEARCH ABOUT DONATE

### What's New

- > COVID-19 - Information for Screening Program Clients
- > COVID-19 - Proof of Vaccine or Negative Test No Longer Required
- > COVID-19 Vaccine Information for Patients

A HEALTHY POPULATION FREE FROM CANCER

**Patient and Family Advisory Council**  
The Patient and Family Advisory Council helps us to blend the voices of patients and families with physicians and staff

**Patient Lodges**  
The Regina and Saskatoon cancer patient lodges offer a home-away-from-home for patients and their companions.

**Guide for New Patients**  
Our Patient Guide section can help you prepare for your first visit to the cancer centre: what to expect, what to bring.

60

**Sask cancer**  
AGENCY

Home Search ...

PATIENTS & FAMILIES SCREENING PREVENTION HEALTH PROFESSIONALS RESEARCH ABOUT DONATE

Home / Patients & Families

### Patients and Families

At the Saskatchewan Cancer Agency, we are focussed on providing you and your family with safe, high quality cancer care and services. Each patient has access to a full team of skilled and dedicated healthcare professionals that are ready to assist you at every step of your cancer journey.

The Saskatchewan Cancer Agency continues to follow current precautionary measures in place in our facilities:

- Mandatory masking remains in place for everyone within our facilities
- Visitor restrictions remain in place to ensure adequate physical distancing can be maintained

**PATIENT GUIDE**

- > Video Introductions for New Patients
- > Before Your First Visit - Forms to Complete
- > Your First Visit to the Cancer Centre
- > Your Cancer Care Journal
- > Your Cancer Care Team
- > Your Cancer Treatment Options
- > Understanding Your Treatment
- > When Treatments are Finished
- > Patient Education Materials
- > Frequently Asked Questions
- > If You Have a Concern
- > Take a TEAM Moment
- > Getting More Information

**PROGRAMS AND SERVICES**

- > Flu Season: Information on Vaccines and Clinics
- > Counseling
- > Screening for Distress
- > Symptom Management and Palliative Care Clinic
- > Smoking Cessation - Benefits of Quitting Tobacco Use
- > Managing Fatigue
- > Nutrition and Cancer
- > Pharmacy
- > Advance Care Planning
- > Support Services Calendars

8/19/2022 61

61

### Video Introductions for New Patients

A diagnosis of cancer can be overwhelming. Knowing what to expect can help.

Join Costa Maragos and Trish Cheveldayoff, both former cancer patients, as they guide you through what to expect as you begin treatment and tour you through the Allan Blair Cancer Centre in Regina and the Saskatoon Cancer Centre:

- [What You Need to Know After a New Cancer Diagnosis](#)
- [What to Expect with Chemotherapy](#)
- [What to Expect with Radiation Therapy](#)
- [Allan Blair Cancer Centre](#)
- [Saskatoon Cancer Centre](#)

Please note, each video will open in YouTube.

8/19/2022 62

62

# Drug information for patients

CCO Cancer Care Ontario Ontario Renal Network Recently Viewed EN | FR

CCO Cancer Care Ontario HOME DRUG FORMULARY GUIDELINES & ADVICE PATHWAY MAPS DATA & RESEARCH

Drugs Regimens Funding & Reimbursement Side Effects Drug Safety & Information Pre-Printed Orders What's New

COVID-19: Get the latest updates or take a self-assessment

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at [Systemic Treatment Regimens During COVID-19](#)

Home / Cancer Treatments / Chemotherapy / Drug Formulary

## DRUG FORMULARY

About the Drug Formulary  
Email Drug Formulary Team

abiraterone  
A BCSB Review  
Funding: (Individual Access Program)

Other Names: (Drug) Appearance: (table) in various colors and strengths

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Drug Monograph  
Jul 2021  
View Monograph  
View Table of Contents

Patient Info Sheet  
Feb 2022  
View Patient Info Sheet

What it is used for

- For treating prostate cancer along with another medication such as prednisone.

PDF Patient Info Sheet En  
PDF Patient Info Sheet Fr

Cancer Care Ontario is the agency standard for patient information

63

Menu Health Professionals / Clinical Resources / [Cancer Drug Manual](#) SHARE

## Drug Index

The Cancer Drug Manual® provides concise, evaluative information on drugs used in oncology. Inclusion in this index is not an indication of the funding status of a drug through BC Cancer. To determine drug coverage, see Benefit Drug List.

Cancer Drug Manual >

A B C D E F G H I J  
K L M N O P Q R S T  
U V W X Y Z

Abemaciclib Monograph >  
Abemaciclib Patient Handout >  
Abiraterone Monograph >  
Abiraterone Patient Handout >

64

The screenshot shows the BC Cancer website page for "Managing Symptoms & Side Effects". The page features a navigation menu with options like "Our Services", "Health Info", "Our Research", "About", "Contact", "Health Professionals", "Donate", and "Careers". A search bar is located at the top right. The main content area includes a heading "Managing Symptoms & Side Effects" and a sub-heading "Managing the pain and physical symptoms and side effects that come with cancer can be difficult. This information will help you understand what you or your loved one are going through and prepare you for what may happen." Below this, there are instructions to "Choose a symptom or side effect from the list below, or use the alphabet links to jump to the item you're looking for." The alphabet links are: A - B - C - **D** - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X. To the right, under the heading "D", there is a list of related links: "Diarrhea Caused by Medications", "Dry Mouth & Mouth Pain", "Dysarthria/Dysglossia: see [Communication Difficulties](#)", "Dysphagia: see [Swallowing Difficulties](#)", "Dysphonia: see [Communication Difficulties](#)", and "Dyspnea: see [Breathlessness](#)".

65

The screenshot shows the header and navigation of the CAPhO (Canadian Association of Pharmacy in Oncology) website. The header includes the CAPhO logo and the text "Canadian Association of Pharmacy in Oncology". A search bar is located to the right of the logo. The navigation menu includes links for "Home", "Sponsors", "Reach Our Members", "Contact", "Member Login", and "Select Language". Below the navigation menu, there is a row of four images with labels: "Engage" (showing a group of people), "Learn" (showing a person at a computer), "Participate" (showing a city skyline), and "Connect" (showing two people talking).

66



67



68